Brisbane, Australia, 30 June 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Ilara Health, a Kenyan company working to make healthcare diagnostic services more accessible, affordable and accurate in Africa, are today pleased to announce that Ilara Health will conduct a three month evaluation of ResAppDx, ResApp’s smartphone app for acute respiratory disease diagnosis, at five partner medical facility sites in Kenya. The evaluation is expected to start during the third quarter of this calendar year.
Over 500 million people in Africa struggle to access high quality healthcare, with many doctors across the continent having a limited ability to perform diagnostics in their clinic. According to the WHO, lower respiratory tract infections are the leading cause of death in Africa, resulting in nearly a million deaths in 2016.
ResAppDx is the world’s first regulatory-approved smartphone app that provides doctors with a low-cost, convenient and accurate point-of-care diagnostic tool to aid in the diagnosis of respiratory diseases such as lower respiratory tract disease, pneumonia, asthma exacerbations and COPD exacerbations.
“With respiratory symptoms the most common presentation to healthcare facilities, we are excited by the benefits that a low-cost and accurate respiratory diagnostic test can bring to healthcare facilities in Kenya,” said Emilian Popa, CEO and Co-founder of Ilara Health. “ResApp’s smartphone-based technology is an ideal fit for our technology platform, which aims to lower the cost of diagnostics and make them accessible and affordable to the 500 million people in Africa who today struggle to access even basic blood tests.”
“We are pleased to be working with a partner who has significant experience in dealing with the challenges of operating in areas which lack modern healthcare infrastructure. Ilara Health also offers innovative financing options that allow their customers to access latest developments in diagnostic technology at a low initial cost. We hope that by providing a low-cost diagnostic test in areas unable to be served by traditional healthcare, we can play a role in improving healthcare for all,” added Tony Keating, CEO and Managing Director of ResApp.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
About Ilara Health
Ilara Health is a Kenya-based health technology company addressing the lack of accessible and accurate diagnostics across sub-Saharan Africa. Ilara Health partners with next generation point of care, regulatory-approved medical device manufacturers that use new technologies to achieve substantial cost reductions in equipment for primary care clinics. Since its inception in 2019, Ilara Health has worked with 100+ small to medium-sized Kenyan clinics and medical centres, providing these facilities with access to novel diagnostics tools and to Ilara Health’s technology platform. Through Ilara Health’s smart financing options, primary care facilities can now offer previously inaccessible, life-saving tests, improving the quality of care they are able to provide to their communities. The long-term mission is to make basic diagnostics affordable and accessible to the 500m people across Africa who struggle to access even a simple blood test. For more information, please visit www.ilarahealth.com.
Contacts for ResApp Health
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
VP, Corporate Affairs
+61 412 281 780
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.